BRAF and breast cancer: The efficiency of targeted cancer therapies in drug-sensitive genotypes such as HER2 amplified breast cancer, B-Raf mutant melanoma and ALK translocated non-small cell lung cancer (NSCLC) is significantly inhibited by treatment resistance.